Abstract

BARILARO, Giuseppe; ESPINOSA, Gerard  and  CERVERA, Ricard. The antiphospholipid syndrome. Rev.Colomb.Reumatol. [online]. 2021, vol.28, suppl.2, pp.166-176.  Epub May 03, 2024. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2021.03.012.

APS is a hypercoagulability condition characterized by the development of thrombosis and pregnancy morbidity (recurrent early miscarriages, fetal deaths after the 10th week of gestation and/or premature births), that occur in patients with antiphospholipid antibodies, namely lupus anticoagulant, anticardiolipin antibodies, and anti-(32-glycoprotein-I antibodies. It is usually isolated but can occur in the setting of another autoimmune disease, mainly systemic lupus erythematosus. Moreover antiphospholipid antibodies can be found in individuals without the disease. Treatment of thrombosis is based on indefinite anticoagulation while low-dose aspirin and low molecular weight heparin are the cornerstone of pregnancy morbidity treatment. Catastrophic antiphospholipid syndrome is treated with anticoagulation, plasma-exchange, and corticosteroids. Standardization of serological assays, inclusion of other antibodies and manifestations in the classification criteria, treatment of non-criteria manifestations and refractory cases are areas of uncertainty.

Keywords : Antiphospholipid syndrome; Anticardiolipin Beta2-glicoprotein I; Lupus anticoagulant; Oral anticoagulation; Heparin.

        · abstract in Spanish     · text in English     · English ( pdf )